Compare Fidelity National Information Servcs Inc (FIS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Fidelity National Information Servcs Inc trades at $35.84 (market cap $18.15B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Fidelity National Information Servcs Inc is far larger — about 2.4× Spyre Therapeutics Inc. Common Stock's market cap, and Fidelity National Information Servcs Inc pays a 5% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 89 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FIS | SYRE | |
|---|---|---|
Market Cap | $18.15B | $7.52B |
Volume | 8,219,694 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $67.94 | $108.92 |
52-Week Low | $32.44 | $22.18 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $38.66B | $6.52B |
Dividend Yield | 5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS (Fidelity National Information Services) trades at $35.20, up 2.74% today, with a bearish technical signal but strong fundamentals including a low P/E of 5.41 and net income margin of 27.65%. Recent earnings have mostly beaten estimates, and the company is expanding its core banking and embedded finance platforms, as seen with new client wins like Kredittbanken (Business Wire, September 30, 2026).
The outlook is mixed: analyst consensus is bullish with a $45.50 price target, but risks include high debt levels and volatile cash flows. Upside potential exists from revenue growth and modernization efforts, while downside risks stem from execution challenges and macroeconomic pressures.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
